Login to Your Account



Pieris, Servier ink $1.2B immuno-oncology pact focusing on bispecific anticalins

By Cormac Sheridan
Staff Writer

Thursday, January 5, 2017

DUBLIN – Pieris Pharmaceuticals Inc. could earn more than €1.126 billion from a broadly based co-development alliance in immuno-oncology with Les Laboratoires Servier SAS.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription